Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medicare PBM Formulary Standards Set By Drug Cmte. Under Graham Bill

Executive Summary

A Medicare Prescription Drug Advisory Committee would be established to develop drug formulary standards for pharmacy benefit management companies participating in the Medicare outpatient drug program under Sen. Graham's (D-Fla.) proposal.

You may also be interested in...



AARP Medicare Rx “Reserve” Proposal Seeks To Bypass Cost Debate

AARP is suggesting tapping the Medicare trust fund surplus as a way to finesse the cost-estimate barrier to a comprehensive prescription drug benefit

AARP Medicare Rx “Reserve” Proposal Seeks To Bypass Cost Debate

AARP is suggesting tapping the Medicare trust fund surplus as a way to finesse the cost-estimate barrier to a comprehensive prescription drug benefit

Formulary Cost-Sharing In Patients' Rights Bill Likely Awaits Conference Cmte

Cost-sharing for non-formulary drugs in the patients' bill of rights is likely to be finalized in conference committee.

Related Content

UsernamePublicRestriction

Register

PS038149

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel